Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

The Volocopter insolvency saga may not be over, just yet. Just days after laying off all of its entire staff and entering insolvency proceedings, the troubled German eVTOL developer may have found a ...

News and analysis covering cutting-edge aviation technology and business models, including zero-carbon propulsion, eVTOL aircraft, automation and autonomy, and new infrastructure.

After hours: March 13 at 7:56:14 PM EDT Loading Chart for BMY ...

After hours: March 12 at 7:45:57 PM EDT Loading Chart for EVTL ...